Serial biopharma entrepreneur David Hung’s Nuvation Bio had been struggling to inspire investors, but a buyout of AnHeart Therapeutics has transformed its prospects overnight.
Key Takeaways
-
The deal to acquire Anheart and its two cancer candidates has seen Nuvation’s share price soar
The all-share deal is worth around $270m and provides Nuvation with the China biotech’s two potentially best-in-class drugs, including the...








